Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Purpose The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2018-10, Vol.171 (3), p.737-745 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 745 |
|---|---|
| container_issue | 3 |
| container_start_page | 737 |
| container_title | Breast cancer research and treatment |
| container_volume | 171 |
| creator | Kim, Ji-Yeon Lim, Ji Eun Jung, Hae Hyun Cho, Soo Youn Cho, Eun Yoon Lee, Se Kyung Yu, Jong Han Lee, Jeong Eon Kim, Seok Won Nam, Seok Jin Park, Yeon Hee Ahn, Jin Seok Im, Young-Hyuck |
| description | Purpose
The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.
Methods
We conducted a retrospective analysis of women with stage I, II, or III BC who underwent curative surgery with/without adjuvant systemic therapy at Samsung Medical Center between July 2004 and December 2008.
Results
Of 3,208 BCs, this study was analyzed using the information of 2,790 BC patients. Hormone receptor-positive (HR+) and human epidermal growth factor 2 (HER2)− BCs were observed in 62.9% of BCs, HR+/ HER2+ in 9.3%, HR−/HER2− in 17.0%, and HR−/HER2+ in 10.8%. In survival analysis, we observed 245 distant recurrences and 198 deaths caused by BC progression. The median follow-up duration was 116.2 months. 10-year disease-specific survival (DSS) rates according to the AJCC 7th edition criteria were 97.2% of stage IA, 100% of IB, 94.9% of IIA, 87.9% of IIB, 86.4% of IIIA, 95.7% of IIIB, and 65.7% of IIIC (
p
|
| doi_str_mv | 10.1007/s10549-018-4858-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2058501299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A552568341</galeid><sourcerecordid>A552568341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-789ae7786180e4c732330077961106177b4c9c5b31be57a7d4f8da78698db8b83</originalsourceid><addsrcrecordid>eNp1kktv1DAUhS0EosPAD2CDLCEhNil2Euc6y9GIpwpsClvLcW4mrjJ2sT2q6KZ_vY5S6EMgLyz5fufI9-gQ8pKzY84YvIucibotGJdFLYUsLh-RFRdQFVByeExWjDdQNJI1R-RZjGeMsRZY-5QclW1b8bpsVuTqp55sr5P1jvqBphGpwwu6-bLdUrS7MY0Ue3t3fPrtKzWTjtEO1izCwQfaBdQxUaOdwUAvbBZqGq3bTVgYdAkfIsaPPqTn5Mmgp4gvbu41-fHh_en2U3Hy_ePn7eakMDWwVIBsNQLIhkuGtYGqrKqcALQN56zhAF1tWiO6incoQENfD7LXmW9l38lOVmvydvE9D_7XAWNSexsNTpN26A9RlUxIwfgczJq8foCe-UNw-XczBVBWwOQttdMTKusGn4I2s6naCFGKRlY1z9TxP6h8etxb4x0ONr_fE7y5IxhRT2mMfjrMOcf7IF9AE3yMAQd1Huxeh9-KMzW3Qy3tULkdam6HusyaVzebHbo99n8Vf-qQgXIBYh65HYbb1f_veg3vEsHp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2057723708</pqid></control><display><type>article</type><title>Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kim, Ji-Yeon ; Lim, Ji Eun ; Jung, Hae Hyun ; Cho, Soo Youn ; Cho, Eun Yoon ; Lee, Se Kyung ; Yu, Jong Han ; Lee, Jeong Eon ; Kim, Seok Won ; Nam, Seok Jin ; Park, Yeon Hee ; Ahn, Jin Seok ; Im, Young-Hyuck</creator><creatorcontrib>Kim, Ji-Yeon ; Lim, Ji Eun ; Jung, Hae Hyun ; Cho, Soo Youn ; Cho, Eun Yoon ; Lee, Se Kyung ; Yu, Jong Han ; Lee, Jeong Eon ; Kim, Seok Won ; Nam, Seok Jin ; Park, Yeon Hee ; Ahn, Jin Seok ; Im, Young-Hyuck</creatorcontrib><description>Purpose
The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.
Methods
We conducted a retrospective analysis of women with stage I, II, or III BC who underwent curative surgery with/without adjuvant systemic therapy at Samsung Medical Center between July 2004 and December 2008.
Results
Of 3,208 BCs, this study was analyzed using the information of 2,790 BC patients. Hormone receptor-positive (HR+) and human epidermal growth factor 2 (HER2)− BCs were observed in 62.9% of BCs, HR+/ HER2+ in 9.3%, HR−/HER2− in 17.0%, and HR−/HER2+ in 10.8%. In survival analysis, we observed 245 distant recurrences and 198 deaths caused by BC progression. The median follow-up duration was 116.2 months. 10-year disease-specific survival (DSS) rates according to the AJCC 7th edition criteria were 97.2% of stage IA, 100% of IB, 94.9% of IIA, 87.9% of IIB, 86.4% of IIIA, 95.7% of IIIB, and 65.7% of IIIC (
p
< 0.001). After applying 8th edition criteria, the 10-year DSS rates were 98.1% of stage IA, 97.7% of IB, 93.8% of IIA, 92.7% of IIB, 88.2% of IIIA, 80.8% of IIIB, and 70.3% of IIIC (
p
< 0.001).
Conclusions
The AJCC 8th edition clinical staging system provides a good prognostic value and addresses the weakness of the AJCC 7th edition, which uses only anatomical pathologic staging.</description><identifier>ISSN: 0167-6806</identifier><identifier>ISSN: 1573-7217</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-018-4858-z</identifier><identifier>PMID: 29931426</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - therapy ; Cancer research ; Cancer staging ; Classification ; Development and progression ; Epidemiology ; Epidermal growth factor ; ErbB-2 protein ; Female ; Gene expression ; Humans ; Medical centers ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Oncology ; Practice Guidelines as Topic ; Prognosis ; Retrospective Studies ; Surgery ; Survival ; Survival analysis ; Tomography, X-Ray Computed ; Young Adult</subject><ispartof>Breast cancer research and treatment, 2018-10, Vol.171 (3), p.737-745</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Breast Cancer Research and Treatment is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-789ae7786180e4c732330077961106177b4c9c5b31be57a7d4f8da78698db8b83</citedby><cites>FETCH-LOGICAL-c470t-789ae7786180e4c732330077961106177b4c9c5b31be57a7d4f8da78698db8b83</cites><orcidid>0000-0001-6459-8118</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-018-4858-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-018-4858-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29931426$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Ji-Yeon</creatorcontrib><creatorcontrib>Lim, Ji Eun</creatorcontrib><creatorcontrib>Jung, Hae Hyun</creatorcontrib><creatorcontrib>Cho, Soo Youn</creatorcontrib><creatorcontrib>Cho, Eun Yoon</creatorcontrib><creatorcontrib>Lee, Se Kyung</creatorcontrib><creatorcontrib>Yu, Jong Han</creatorcontrib><creatorcontrib>Lee, Jeong Eon</creatorcontrib><creatorcontrib>Kim, Seok Won</creatorcontrib><creatorcontrib>Nam, Seok Jin</creatorcontrib><creatorcontrib>Park, Yeon Hee</creatorcontrib><creatorcontrib>Ahn, Jin Seok</creatorcontrib><creatorcontrib>Im, Young-Hyuck</creatorcontrib><title>Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.
Methods
We conducted a retrospective analysis of women with stage I, II, or III BC who underwent curative surgery with/without adjuvant systemic therapy at Samsung Medical Center between July 2004 and December 2008.
Results
Of 3,208 BCs, this study was analyzed using the information of 2,790 BC patients. Hormone receptor-positive (HR+) and human epidermal growth factor 2 (HER2)− BCs were observed in 62.9% of BCs, HR+/ HER2+ in 9.3%, HR−/HER2− in 17.0%, and HR−/HER2+ in 10.8%. In survival analysis, we observed 245 distant recurrences and 198 deaths caused by BC progression. The median follow-up duration was 116.2 months. 10-year disease-specific survival (DSS) rates according to the AJCC 7th edition criteria were 97.2% of stage IA, 100% of IB, 94.9% of IIA, 87.9% of IIB, 86.4% of IIIA, 95.7% of IIIB, and 65.7% of IIIC (
p
< 0.001). After applying 8th edition criteria, the 10-year DSS rates were 98.1% of stage IA, 97.7% of IB, 93.8% of IIA, 92.7% of IIB, 88.2% of IIIA, 80.8% of IIIB, and 70.3% of IIIC (
p
< 0.001).
Conclusions
The AJCC 8th edition clinical staging system provides a good prognostic value and addresses the weakness of the AJCC 7th edition, which uses only anatomical pathologic staging.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer research</subject><subject>Cancer staging</subject><subject>Classification</subject><subject>Development and progression</subject><subject>Epidemiology</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Medical centers</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Practice Guidelines as Topic</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Tomography, X-Ray Computed</subject><subject>Young Adult</subject><issn>0167-6806</issn><issn>1573-7217</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kktv1DAUhS0EosPAD2CDLCEhNil2Euc6y9GIpwpsClvLcW4mrjJ2sT2q6KZ_vY5S6EMgLyz5fufI9-gQ8pKzY84YvIucibotGJdFLYUsLh-RFRdQFVByeExWjDdQNJI1R-RZjGeMsRZY-5QclW1b8bpsVuTqp55sr5P1jvqBphGpwwu6-bLdUrS7MY0Ue3t3fPrtKzWTjtEO1izCwQfaBdQxUaOdwUAvbBZqGq3bTVgYdAkfIsaPPqTn5Mmgp4gvbu41-fHh_en2U3Hy_ePn7eakMDWwVIBsNQLIhkuGtYGqrKqcALQN56zhAF1tWiO6incoQENfD7LXmW9l38lOVmvydvE9D_7XAWNSexsNTpN26A9RlUxIwfgczJq8foCe-UNw-XczBVBWwOQttdMTKusGn4I2s6naCFGKRlY1z9TxP6h8etxb4x0ONr_fE7y5IxhRT2mMfjrMOcf7IF9AE3yMAQd1Huxeh9-KMzW3Qy3tULkdam6HusyaVzebHbo99n8Vf-qQgXIBYh65HYbb1f_veg3vEsHp</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Kim, Ji-Yeon</creator><creator>Lim, Ji Eun</creator><creator>Jung, Hae Hyun</creator><creator>Cho, Soo Youn</creator><creator>Cho, Eun Yoon</creator><creator>Lee, Se Kyung</creator><creator>Yu, Jong Han</creator><creator>Lee, Jeong Eon</creator><creator>Kim, Seok Won</creator><creator>Nam, Seok Jin</creator><creator>Park, Yeon Hee</creator><creator>Ahn, Jin Seok</creator><creator>Im, Young-Hyuck</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6459-8118</orcidid></search><sort><creationdate>20181001</creationdate><title>Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort</title><author>Kim, Ji-Yeon ; Lim, Ji Eun ; Jung, Hae Hyun ; Cho, Soo Youn ; Cho, Eun Yoon ; Lee, Se Kyung ; Yu, Jong Han ; Lee, Jeong Eon ; Kim, Seok Won ; Nam, Seok Jin ; Park, Yeon Hee ; Ahn, Jin Seok ; Im, Young-Hyuck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-789ae7786180e4c732330077961106177b4c9c5b31be57a7d4f8da78698db8b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer research</topic><topic>Cancer staging</topic><topic>Classification</topic><topic>Development and progression</topic><topic>Epidemiology</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Medical centers</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Practice Guidelines as Topic</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Tomography, X-Ray Computed</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Ji-Yeon</creatorcontrib><creatorcontrib>Lim, Ji Eun</creatorcontrib><creatorcontrib>Jung, Hae Hyun</creatorcontrib><creatorcontrib>Cho, Soo Youn</creatorcontrib><creatorcontrib>Cho, Eun Yoon</creatorcontrib><creatorcontrib>Lee, Se Kyung</creatorcontrib><creatorcontrib>Yu, Jong Han</creatorcontrib><creatorcontrib>Lee, Jeong Eon</creatorcontrib><creatorcontrib>Kim, Seok Won</creatorcontrib><creatorcontrib>Nam, Seok Jin</creatorcontrib><creatorcontrib>Park, Yeon Hee</creatorcontrib><creatorcontrib>Ahn, Jin Seok</creatorcontrib><creatorcontrib>Im, Young-Hyuck</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Ji-Yeon</au><au>Lim, Ji Eun</au><au>Jung, Hae Hyun</au><au>Cho, Soo Youn</au><au>Cho, Eun Yoon</au><au>Lee, Se Kyung</au><au>Yu, Jong Han</au><au>Lee, Jeong Eon</au><au>Kim, Seok Won</au><au>Nam, Seok Jin</au><au>Park, Yeon Hee</au><au>Ahn, Jin Seok</au><au>Im, Young-Hyuck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>171</volume><issue>3</issue><spage>737</spage><epage>745</epage><pages>737-745</pages><issn>0167-6806</issn><issn>1573-7217</issn><eissn>1573-7217</eissn><abstract>Purpose
The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.
Methods
We conducted a retrospective analysis of women with stage I, II, or III BC who underwent curative surgery with/without adjuvant systemic therapy at Samsung Medical Center between July 2004 and December 2008.
Results
Of 3,208 BCs, this study was analyzed using the information of 2,790 BC patients. Hormone receptor-positive (HR+) and human epidermal growth factor 2 (HER2)− BCs were observed in 62.9% of BCs, HR+/ HER2+ in 9.3%, HR−/HER2− in 17.0%, and HR−/HER2+ in 10.8%. In survival analysis, we observed 245 distant recurrences and 198 deaths caused by BC progression. The median follow-up duration was 116.2 months. 10-year disease-specific survival (DSS) rates according to the AJCC 7th edition criteria were 97.2% of stage IA, 100% of IB, 94.9% of IIA, 87.9% of IIB, 86.4% of IIIA, 95.7% of IIIB, and 65.7% of IIIC (
p
< 0.001). After applying 8th edition criteria, the 10-year DSS rates were 98.1% of stage IA, 97.7% of IB, 93.8% of IIA, 92.7% of IIB, 88.2% of IIIA, 80.8% of IIIB, and 70.3% of IIIC (
p
< 0.001).
Conclusions
The AJCC 8th edition clinical staging system provides a good prognostic value and addresses the weakness of the AJCC 7th edition, which uses only anatomical pathologic staging.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29931426</pmid><doi>10.1007/s10549-018-4858-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6459-8118</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2018-10, Vol.171 (3), p.737-745 |
| issn | 0167-6806 1573-7217 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2058501299 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Biomarkers Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - therapy Cancer research Cancer staging Classification Development and progression Epidemiology Epidermal growth factor ErbB-2 protein Female Gene expression Humans Medical centers Medicine Medicine & Public Health Middle Aged Neoplasm Grading Neoplasm Staging Oncology Practice Guidelines as Topic Prognosis Retrospective Studies Surgery Survival Survival analysis Tomography, X-Ray Computed Young Adult |
| title | Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T18%3A17%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20the%20new%20AJCC%20eighth%20edition%20of%20the%20TNM%20classification%20for%20breast%20cancer%20with%20a%20single-center%20breast%20cancer%20cohort&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Kim,%20Ji-Yeon&rft.date=2018-10-01&rft.volume=171&rft.issue=3&rft.spage=737&rft.epage=745&rft.pages=737-745&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-018-4858-z&rft_dat=%3Cgale_proqu%3EA552568341%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2057723708&rft_id=info:pmid/29931426&rft_galeid=A552568341&rfr_iscdi=true |